Changes in Gene Expression and Prognosis of Blood Immune Cells After Cardiopulmonary Bypass Surgery

Second Affiliated Hospital, School of Medicine, Zhejiang University1 site in 1 country12 target enrollmentMay 17, 2023

ConditionsAcute Kidney Injury

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Acute Kidney Injury
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment: 12
Locations: 1
Primary Endpoint: Postoperative acute kidney injury
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The goal of this observational study is to learn about the changes in gene expression in blood immune cells in after cardiac surgery with cardiopulmonary bypass.The main question it aims to answer is: What specific gene expression changes predict kidney damage after cardiac surgery with cardiopulmonary bypass. Participants received conventional treatment.

Registry

clinicaltrials.gov

Start Date

May 17, 2023

End Date

July 10, 2023

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age≥ 18 years old; 2) Cardiopulmonary bypass descending valve replacement (molding), or coronary artery bypass grafting, or macrovascular surgery.

Exclusion Criteria

•any cognitive or mental impairment that is unable to sign the informed consent form; 2) Have basic immune system and blood system diseases; 3) pregnancy; 4) Receiving radiotherapy and chemotherapy before surgery; 5) Receiving immunosuppressive drugs within six months; 6) Have participated in other interventional clinical trials within 30 days before surgery.
•Exit Criteria:
•Incomplete surgery;
•Secondary transfer in the operating room;
•Automatically request to terminate the test.